ClinicalMind Completes Capital Restructuring Led by Renovus Capital Partners to Expand Strategic Agency Services and enGauge® Technology Platform

VCBeat (WeChat ID: vcbeat) learned from foreign media reports that on November 25, 2019, ClinicalMind, LLC, a leading global medical communications company, announced the completion of its recapitalization. The recapitalization was led by an equity financing round conducted by Renovus Capital Partners (Renovus).

During this capital restructuring, Excel Partners served as the sell-side advisor to ClinicalMind. DLA Piper acted as legal counsel to Renovus, and Brown Rudnick acted as legal counsel to ClinicalMind.

Following the recapitalization, ClinicalMind will expand its strategic agency business and continue to innovate its enGauge® technology.

ClinicalMind, founded in 2012 and headquartered in New York, USA, is a leading medical communications company. Its leadership team comprises seasoned professionals with over 20 years of experience working in the United States and around the globe. At the forefront of therapeutic innovation, ClinicalMind is renowned for its extensive experience as a strategic partner to biotechnology and pharmaceutical companies, particularly those preparing to launch novel and first-in-class therapies.

As a leading healthcare communications company, ClinicalMind translates medical science into clinical, economic, and social value throughout the lifecycle of therapeutic products. ClinicalMind’s dedication to scientific strategy, operational excellence, and technological superiority drives its support for numerous innovative initiatives in rapidly evolving specialized fields, including gene and cell therapies as well as novel treatments for various rare diseases.

ClinicalMind integrates scientific and patented technologies to enhance effective communication among healthcare practitioners and other stakeholders in the United States and globally.

Furthermore, ClinicalMind has garnered widespread industry recognition for its premier technology solutions, which drive physician engagement, facilitate internal communication between marketing and medical affairs teams, and deliver program development solutions via a SaaS model. ClinicalMind’s SaaS products streamline workflows and virtual advisory boards, monitor program progress, support contract management, track all activities, and generate meaningful data along with all necessary compliance reports. These technology solutions significantly enhance engagement among clinicians and produce critical data to help clients better understand and more effectively execute their therapeutic initiatives.

Jeanne Martel, CEO of ClinicalMind, stated, “The rapid growth of ClinicalMind is a testament to the team’s hard work and innovative thinking. We are excited to establish a new partnership with Renovus, as it will enable us to sustain our growth and expand our service and technology solutions to meet customer needs.”

Jesse Serventi, Founding Partner at Renovus, stated, “After an extensive search, we are delighted to partner with an outstanding medical communications company and management team that are transforming the healthcare landscape. They continue to address the rapid evolution of rare diseases and the advancement of high-tech approaches such as gene and cell therapies. We are excited about their fully integrated technology platform and solutions, developed by a team with a deep understanding of clients’ technical needs. We look forward to helping them scale this technology to support biotechnology and pharmaceutical companies.”

Renovus Capital Partners (Renovus), founded in 2010, is a private equity firm focused on education, training, and human capital. Headquartered in the Philadelphia suburbs, Renovus manages over $500 million in committed capital through two SBIC funds. To date, the firm has acquired 25 portfolio companies in the education and training, technology, and healthcare services sectors. As an active investor in profitable, growth-oriented enterprises, the Renovus team collaborates with management to create value through operational improvements, strategic growth initiatives, and acquisitions.

(Compiled by Wang Fang)